BusinessCellular Biomedicine Group Announces Results of 2017 Annual Meeting of StockholdersBy Nasdaq OMXMay 1, 2017, 8:01 PM UTC
BusinessPoseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual MeetingBy Nasdaq OMXApr 4, 2017, 12:01 PM UTC
BusinessPoseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual MeetingBy Nasdaq OMXApr 4, 2017, 12:01 PM UTC
BusinessCell Design Labs Announces Issuance of Broad Patent for Programmable Car-T Cells to Treat Cancer and Other DiseasesBy Nasdaq OMXMar 15, 2017, 12:01 PM UTC
BusinessCell Design Labs Announces Issuance of Broad Patent for Programmable Car-T Cells to Treat Cancer and Other DiseasesBy Nasdaq OMXMar 15, 2017, 12:01 PM UTC
BusinessCellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in ChinaBy Nasdaq OMXJan 9, 2017, 11:11 AM UTC
BusinessPoseida Therapeutics Presents Preclinical Data Demonstrating Tumor Response from BCMA-Specific CAR-T Program at American Society of Hematology Annual MeetingBy Nasdaq OMXDec 5, 2016, 6:00 PM UTC
BusinessSurefire Medical Receives Grant to Pursue Phase 1b Clinical Trial of CAR-T Immunotherapy Delivery through Precision Infusion SystemBy Nasdaq OMXNov 15, 2016, 11:00 AM UTC
